A study found that the m6A demethylase FTO was inhibited by the oncometabolite R-2-hydroxyglutarate (R-2HG), leading to increased methylation of acute myeloid leukemia (AML) and glioma cells and reduced mRNA expression of c-MYC and CEBPA, thereby blocking cell proliferation and the cell cycle and inducing apoptosis, which play a therapeutic role in AML and glioma (Qing et al., 2021). This evidence concerns the gene FTO and central nervous system cancer.